A systematic review and meta-analysis of clinician-reported versus patient-reported outcomes of radiation dermatitis

Emily Lam, Caitlin Yee, Gina Wong, Marko Popovic, Leah Drost, Kucy Pon, Danny Vesprini, Henry Lam, Saleh Aljabri, Hany Soliman, Carlo DeAngelis, Edward Chow, Emily Lam, Caitlin Yee, Gina Wong, Marko Popovic, Leah Drost, Kucy Pon, Danny Vesprini, Henry Lam, Saleh Aljabri, Hany Soliman, Carlo DeAngelis, Edward Chow

Abstract

Radiation dermatitis is a common adverse effect of radiotherapy (RT) in breast cancer patients. Although radiation dermatitis is reported by either the clinician or the patient, previous studies have shown disagreement between clinician-reported outcomes (CROs) and patient-reported outcomes (PROs). This review evaluated the extent of discordance between CROs and PROs for radiation dermatitis. Studies reporting both clinician and patient-reported outcomes for external beam RT were eligible. Nine studies met the inclusion criteria for the systematic review, while 8 of these studies were eligible for inclusion in a meta-analysis of acute and late skin toxicities. We found an overall agreement between CROs and PROs of acute skin colour change, fibrosis and/or retraction, and moist desquamation (p > 0.005). Reporting of late breast pain, breast edema, skin colour change, telangiectasia, fibrosis and/or retraction and induration/fibrosis alone (p > 0.005) were also in agreement between clinicians and patients. Our meta-analysis revealed a greater reporting of acute breast pain by patients (RR = 0.89, 95% CI 0.87-0.92, p < 0.001), greater reporting of acute breast edema by physicians (RR = 1.80, 95% CI 1.65-1.97, p < 0.001) and a greater reporting of late breast shrinkage by patients (RR = 0.61, 95% CI 0.44-0.86, p = 0.005). However, our review was limited by the discrepancies between PRO and CRO measurement tools as well as the absence of standard time points for evaluation of radiation dermatitis. Given potential discrepancies between CROs and PROs, both measures should be reported in future studies. Ultimately, we advocate for the development of a single tool to assess symptoms from both perspectives.

Keywords: Radiation dermatitis; Radiotherapy; Review; breast cancer.

Copyright © 2019 Elsevier Ltd. All rights reserved.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram.
Fig. 2
Fig. 2
Acute skin toxicity.
Fig. 3
Fig. 3
Late skin toxicity.
Fig. 3
Fig. 3
Late skin toxicity.

References

    1. Harper J.L., Franklin L.E., Jenrette J.M., Aguero E.G. Skin toxicity during breast irradiation: pathophysiology and management. South Med J. 2004;97:989–994.
    1. McQuestion M. Evidence-based skin care management in radiation Therapy: clinical Update. Semin Oncol Nurs. 2011;27:e1–e17. doi: 10.1016/J.SONCN.2011.02.009.
    1. Lilla C., Ambrosone C.B., Kropp S., Helmbold I., Schmezer P., von Fournier D. Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Canc Res Treat. 2007;106:143–150. doi: 10.1007/s10549-006-9480-9.
    1. Chen P.Y., Vicini F.A., Benitez P., Kestin L.L., Wallace M., Mitchell C. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation. Cancer. 2006;106:991–999. doi: 10.1002/cncr.21681.
    1. Haviland J.S., Hopwood P., Mills J., Sydenham M., Bliss J.M., Yarnold J.R. Do patient-reported outcome measures agree with clinical and photographic assessments of normal tissue effects after breast radiotherapy? The experience of the standardisation of breast radiotherapy (START) trials in early breast cancer. Clin Oncol. 2016;28 doi: 10.1016/j.clon.2016.01.011.
    1. Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167. doi: 10.1136/bmj.f167.
    1. Neben-Wittich M.A., Atherton P.J., Schwartz D.J., Sloan J.A., Griffin P.C., Deming R.L. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4) Int J Radiat Oncol Biol Phys. 2011;81:397–402. doi: 10.1016/j.ijrobp.2010.05.065.
    1. Trotti A., Colevas A., Setser A., Rusch V., Jaques D., Budach V. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181. doi: 10.1016/S1053-4296(03)00031-6.
    1. Calvert M., Kyte D., Duffy H., Gheorghe A., Mercieca-Bebber R., Ives J. Patient-reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. PLoS One. 2014;9 doi: 10.1371/journal.pone.0110216.
    1. Flores L.T., Bennett A.V., Law E.B., Hajj C., Griffith M.P., Goodman K.A. Patient-reported outcomes vs. Clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res. 2012;5:119–124.
    1. Janssen C., J van Rein E.A., Rui Paulino Pereira N., Raskin K.A., Ferrone M.L., Hornicek F.J. The discrepancy between patient and clinician reported function in extremity bone metastases. Sarcoma. 2016;2016:1014248. doi: 10.1155/2016/1014248.
    1. Basch E., Iasonos A., Mcdonough T.A., Barz A., Culkin A., Kris M.G. 2006. Articles patient versus clinician symptom reporting using the national cancer Institute common terminology criteria for adverse Events: results of a questionnaire-based study.
    1. Preferred reporting items for systematic reviews and meta- analyses [n.d].
    1. Bhattacharya I.S., Haviland J.S., Hopwood P., Coles C.E., Yarnold J.R., Bliss J.M. 2019. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial.
    1. Coles C.E., Griffin C.L., Kirby A.M., Titley J., Agrawal R.K., Alhasso A. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–1060. doi: 10.1016/S0140-6736(17)31145-5.
    1. Kozak K.R., Smith B.L., Adams J., Kornmehl E., Katz A., Gadd M. Accelerated partial-breast irradiation using proton beams: initial clinical experience. Int J Radiat Oncol Biol Phys. 2006;66:691–698. doi: 10.1016/j.ijrobp.2006.06.041.
    1. Jagsi R., Griffith K.A., Boike T.P., Walker E., Nurushev T., Grills I.S. Differences in the acute toxic effects of breast radiotherapy by fractionation schedule. JAMA Oncol. 2015;1:918. doi: 10.1001/jamaoncol.2015.2590.
    1. Sayan M., Wilson K., Nelson C., Gagne H., Rubin D., Heimann R. A novel schedule of accelerated partial breast radiation using intensity-modulated radiation therapy in elderly patients: survival and toxicity analysis of a prospective clinical trial. 2017;35 doi: 10.3857/roj.2016.01963.
    1. Azoury F., Heymann S., Acevedo C., Spielmann M., Vielh P., Garbay J.R. Phase II trial of 3D-conformal accelerated partial breast irradiation: lessons learned from patients and physicians' evaluation. Radiother Oncol. 2012;103:193–198. doi: 10.1016/j.radonc.2012.03.019.
    1. Brouwers P.J.A.M., van Loon J., Houben R.M.A., Paulissen J., Engelen S.M.E., Heuts M. Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10 years of follow up. Radiother Oncol. 2018;126:163–169. doi: 10.1016/j.radonc.2017.08.004.
    1. Mukesh M.B., Qian W., Wah Hak C.C., Wilkinson J.S., Barnett G.C., Moody A.M. The cambridge breast intensity-modulated radiotherapy trial: comparison of clinician- versus patient-reported outcomes. Clin Oncol. 2016;28:354–364. doi: 10.1016/j.clon.2016.02.011.
    1. Cleeland C.S., Ryan K.M. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore. 1994;23:129–138.
    1. Chren M.-M., Lasek R.J., Sahay A.P., Sands L.P. Measurement properties of skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105–110. doi: 10.1007/BF02737863.
    1. Berthelet E., Truong P.T., Musso K., Grant V., Kwan W., Moravan V. Preliminary reliability and validity testing of a new Skin Toxicity Assessment Tool (STAT) in breast cancer patients undergoing radiotherapy. Am J Clin Oncol. 2004;27:626–631.
    1. Cirillo M., Venturini M., Ciccarelli L., Coati F., Bortolami O., Verlato G. Clinician versus nurse symptom reporting using the National Cancer Institute--Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol. 2009;20:1929–1935. doi: 10.1093/annonc/mdp287.
    1. Cuaron J.J., Chon B., Tsai H., Goenka A., DeBlois D., Ho A. Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol. 2015;92:284–291. doi: 10.1016/j.ijrobp.2015.01.005.
    1. Xiao C., Polomano R., Bruner D.W. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 2013;36:E1–E16. doi: 10.1097/NCC.0b013e318269040f.
    1. Cheifetz O., Haley L., Breast Cancer Action B.C. Management of secondary lymphedema related to breast cancer. Can Fam Physician. 2010;56:1277–1284.
    1. Shachar S.S., Hurria A., Muss H.B. Breast cancer in women older than 80 years. J Oncol Pract. 2016;12:123–132. doi: 10.1200/JOP.2015.010207.
    1. Falk Dahl C.A., Reinertsen K.V., Nesvold I.-L., Fosså S.D., Dahl A.A. A study of body image in long-term breast cancer survivors. Cancer. 2010;116:3549–3557. doi: 10.1002/cncr.25251.
    1. Efficace F., Rosti G., Aaronson N., Cottone F., Angelucci E., Molica S. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014;99:788–793. doi: 10.3324/haematol.2013.093724.
    1. Hill-Kayser C.E., Vachani C., Hampshire M.K., Di Lullo G.A., Metz J.M. Cosmetic outcomes and complications reported by patients having undergone breast-conserving treatment. Int J Radiat Oncol Biol Phys. 2012;83:839–844. doi: 10.1016/j.ijrobp.2011.08.013.
    1. Van Den Beuken-Van Everdingen M.H.J., Hochstenbach L.M.J., Joosten E.A.J., Tjan-Heijnen V.C.G., Janssen D.J.A. 2016. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis.
    1. Von Roenn J.H., Cleeland C.S., Gonin R., Hatfield A.K., Pandya K.J. Physician attitudes and practice in cancer pain management: a survey from the eastern cooperative oncology Group. Ann Intern Med. 1993;119:121. doi: 10.7326/0003-4819-119-2-199307150-00005.
    1. Gordon D.B., Dahl J.L., Miaskowski C., McCarberg B., Todd K.H., Paice J.A. American pain society Recommendations for improving the quality of acute and cancer pain management. Arch Intern Med. 2005;165:1574. doi: 10.1001/archinte.165.14.1574.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit